Earnings

AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate

Sep 21, 2026 · 04:55 PM ET· updated 49m ago

AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.46) by 76.09 percent. This is a 91.79 percent increase over losses of $(1.34) per share from the

Why It Matters

AnaptysBio lost less money than Wall Street expected this quarter. The company is improving, which suggests its business is moving in a better direction.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ANAB56.56

+1.35 (+2.45%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.